Samsung SDI to promote ESS battery products in Europe

Samsung SDI Co., South Korea's second-largest battery maker, said Monday it will promote its latest energy storage system battery products at a major European battery exhibition next month.
Samsung SDI will take part in InterBattery Europe 2025, one of the key exhibitions under The Smarter E Europe -- the continent's largest energy industry event -- set to take place in Germany from May 7-9, the company said in a press release.
At this year's show, the company plans to introduce a variety of next-generation batteries, with a special focus on its ESS technology designed for the emerging era of artificial intelligence.
The products on display will include the U8A1, a new battery developed for uninterruptible power supply systems, and the Samsung Battery Box 1.5.
A UPS is a crucial backup system that provides emergency power to facilities like data centers during outages.
The SBB 1.5 boasts improved safety features by using enhanced direct injection technology, which sprays fire-extinguishing agents directly onto battery modules to prevent overheating and thermal spread.
Samsung SDI is the only Korean battery company to be named a finalist for The Smart E Award at this year's event, the release said.
The Smart E Awards honor innovative products and technologies across five categories: energy storage, electric mobility, solar energy, smart energy solutions, and outstanding projects. (Yonhap)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Korea Herald

6 hours ago

• Korea Herald

[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts

Korea Herald correspondent BOSTON — SK Biopharmaceuticals CEO Lee Dong-hoon underscored the company's preparedness for potential US tariff changes and emphasized the critical role of open innovation in shaping the future of global pharmaceuticals. 'We've weathered volatility in our share price over the past year, but the impact of potential price cuts has been minimal,' Lee said Thursday during a press conference on the sidelines of the 2025 Bio USA. 'Our direct-to-market sales model remains fundamentally solid.' He recalled a particularly tense moment earlier this year when shifting US tariff policies posed logistical challenges. In April, the company rushed to transport finished products from Canada into the US before a new tariff deadline. 'When the final truck finally cleared customs, everyone burst into applause,' he recounted. To prevent such risks from recurring, the company now assembles finished products in Canada and ensures shipments cross the border ahead of any policy changes. Looking ahead, SK Biopharmaceuticals is evaluating Puerto Rico as a potential US-based manufacturing site, leveraging its status as a US territory and pharmaceutical hub. 'Canada is cost-effective for now, but we're preparing for every scenario,' Lee said, noting the company's tariff risk is now 'close to zero' for the year. Lee also expressed confidence in the company's long-term growth. 'We've already announced our goal to hit 1 trillion won ($728 million) in sales by 2029, and we're on track,' he said, citing consistent profitability since last year. A cornerstone of SK Biopharmaceuticals' strategy is open innovation. Instead of relying solely on internal research and development, the company is partnering with universities, biotech firms and research institutions. 'Major global pharmaceutical firms are moving away from in-house basic research, and so are we. When you can collaborate and generate results at a fraction of the cost, your possibilities expand," he explained. The CEO emphasized the importance of tapping into underutilized technologies at US universities and biotech startups to diversify the company's pipeline, moving beyond its core focus on epilepsy into areas like oncology. Artificial intelligence is another major focus area. Lee highlighted the company's work on EEG-based seizure prediction models in collaboration with European and South American partners, along with AI algorithm development trials currently underway in Korea. 'AI is no longer optional. It's essential in every part of the business,' he said. One standout partnership is with PhnyX Lab, whose AI-driven automation of clinical documentation significantly reduced paperwork. 'Even our US team, which was initially skeptical, was blown away,' Lee said, calling the shift 'Copernican' in scale for how it will reduce time and cost. The CEO also outlined plans to build a global digital platform for epilepsy patients — a space where patients and physicians can share experiences and insights. 'It's not about selling drugs,' he clarified. 'It's about collecting data to inform AI-powered marketing, drug development and clinical trial design.' The company is looking three to five years ahead, aiming to build an ecosystem where shared data drives innovation across functions. In the US, SK Biopharmaceuticals is intensifying its engagement with health care providers. Lee has personally met with dozens of physicians this year, aiming for 100 meetings, to gather insights that will shape lifecycle strategies such as patent extensions, expanded indications and new formulations like IV delivery. Meanwhile, SK Biopharmaceuticals has invested in targeted TV and YouTube campaigns for its flagship epilepsy drug, Xcopri (cenobamate). Its 'Road to Reduction' campaign drew 9.37 million views in just one month, signaling the brand's growing visibility and leadership in the epilepsy treatment market.

Korea Herald

11 hours ago

• Korea Herald

S. Korea's trade chief vows 'interest-based, pragmatic' trade talks with US

South Korea's trade minister said Sunday he will pursue a "national interest-based and pragmatic" approach in trade negotiations with the United States as he left for Washington for tariff talks with US officials. Trade Minister Yeo Han-koo told reporters that he will focus on "pragmatic and mutually beneficial negotiations based on national interests" in trade talks with the US. Yeo will hold a meeting with US Trade Representative Jamieson Greer and Commerce Secretary Howard Lutnick this week to discuss various trade issues, including tariffs and non-tariff trade measures, and reach out to officials at the White House and the US Congress. South Korea also plans to hold the third round of technical discussions on such issues during this week's visit to Washington, officials said. The ministry said Yeo will address Korea's concerns over US President Donald Trump's administration's hefty tariff measures, including 50 percent tariffs on steel imports and 25 percent duties on imported cars, and discuss mutually beneficial solutions to resolve trade issues between the two countries during his trip to Washington. Yeo will also call for US lawmakers' efforts to create a "stable" and "predictable" environment for Korean companies investing in the US regarding Washington's push to make revisions to tax incentives under the Inflation Reduction Act, the ministry added. "We will do our best to come up with a win-win solution for both South Korea and the US regarding tariff issues and make as many allies as possible within the US to help with Korean companies' businesses," the trade minister said. Seoul and Washington had agreed to craft a package deal covering tariffs, non-tariff measures, economic cooperation and other trade issues by July 8 -- when the US administration's suspension of reciprocal tariffs, including a 25 percent duty for South Korea, will end. (Yonhap)

Korea Herald

13 hours ago

• Korea Herald

Household loans by major banks rise at fastest pace in 10 months in June

Household loans extended by five major banks in South Korea rose at the fastest pace in 10 months, industry data showed Sunday, amid signs of overheating in the housing market and a recent rally in the local stock market. Outstanding household loans extended by the five major commercials banks here, including KB Kookmin Bank and Shinhan Bank, stood at 752.1 trillion won ($547.6 billion) as of Thursday, up 3.99 trillion won from the end of May, according to the data. This translates to a daily increase of 210.2 billion won over the 19-day period in June, the fastest pace since last August, when loans grew by a daily 310.5 billion won. If this trend continues through the end of the month, household loans are expected to increase by 6.3 trillion won in June, marking the largest monthly gain since August last year, when they jumped 9.63 trillion won. By category, outstanding home-backed loans reached 596.6 trillion won as of Thursday, up 2.99 trillion won from the end of May. Unsecured loans also climbed to 104.4 trillion won, increasing by 1.09 trillion won over the same period. Market watchers attributed the recent rise in household loans to strong demand for investment in both the real estate and financial markets. Recent data showed that Seoul's apartment market has been on an upward trajectory for 20 consecutive weeks since turning positive in early February, with the pace of gains accelerating in recent weeks. Apartment prices in the capital city climbed by an average 0.36 percent as of Monday, the biggest weekly increase since the second week of September 2018, when prices rose 0.45 percent. Meanwhile, the local stock market has also been rallying since the new Lee Jae Myung government took office earlier this month. The benchmark Korea Composite Stock Price Index (KOSPI) finished at 3,021.84 points Friday, surpassing the 3,000-point threshold for the first time since Dec. 28, 2021. (Yonhap)